Last reviewed · How we verify

CTGel/ BPO Wash — Competitive Intelligence Brief

CTGel/ BPO Wash (CTGel/ BPO Wash) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination with antimicrobial agent. Area: Dermatology.

phase 3 Topical antibiotic combination with antimicrobial agent Cutibacterium acnes (bacterial target); bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

CTGel/ BPO Wash (CTGel/ BPO Wash) — Stiefel, a GSK Company. CTGel/BPO Wash is a topical formulation combining clindamycin and benzoyl peroxide to reduce acne-causing bacteria and inflammation on the skin.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CTGel/ BPO Wash TARGET CTGel/ BPO Wash Stiefel, a GSK Company phase 3 Topical antibiotic combination with antimicrobial agent Cutibacterium acnes (bacterial target); bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination with antimicrobial agent class)

  1. Stiefel, a GSK Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CTGel/ BPO Wash — Competitive Intelligence Brief. https://druglandscape.com/ci/ctgel-bpo-wash. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: